Non-Small Cell Lung Cancer (NSCLC)
Conditions
Brief summary
Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.
Interventions
DRUGAtezolizumab
Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of locally advanced or metastatic NSCLC (histologically or cytologically confirmed stage IIIB/stage IV) and prior chemotherapy * Decision to be treated with Atezolizumab according to Summary of Product Characteristics (SmPC) by treating physician, independent of this non-interventional study * No contraindication to treatment with Atezolizumab Retrospective Inclusion: * Participants may be included retrospectively. Retrospective inclusion and documentation is limited to up to 9 weeks after initial start of therapy with Atezolizumab (corresponding to a maximum of 3 treatment cycles with drug administrations at 3-week intervals), corresponding to a maximum of 9 weeks prior to date of informed consent. Quality of life for this population will be captured and assessed retrospectively with a modified questionnaire for the period immediately prior to treatment start until study inclusion. participants who started Atezolizumab therapy more than 9 weeks prior to ICF being obtained may not be included in the study. * Participants who give consent to be retrospectively enrolled but have already discontinued Atezolizumab for reasons such as loss of clinical benefit or toxicity may also take part in the study, given their first administration of Atezolizumab is within 9 weeks of consenting to take part, and they meet all other eligibility criteria.
Exclusion criteria
Patients not eligible for Atezolizumab treatment according to SmPC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of response (DOR) to Atezolizumab treatment | Time from first documentation of complete response (CR) or partial response (PR), whichever occurs first, until progressive disease (PD), as evaluated by the physician according to routine practice or death; through the end of study (~ 5 years) |
| Time to loss of clinical benefit (TTLCB) from Atezolizumab treatment | Time from first dose to loss of clinical benefit as assessed by the treating physician, through the end of study (approximately 5 years). |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) of overall population | Time from initiation of study treatment to the first occurrence of progressive disease (PD) or death from any cause, whichever occurs first, as evaluated by the physician according to clinical practice, through the end of study (approximately 5 years) |
| Time to response (TTR) of overall population | Time from first dose to first response as assessed in clinical routine, through the end of study (approximately 5 years) |
| Overall response rate (ORR) of overall population | Rate of CR and PR in patients as assessed in clinical routine, through end of study (approximately 5 years) |
| Best overall response of patients in cohort 2 (Coh2 BOR) | Baseline through the end of study (approximately 5 years) |
| Overall survival of cohort 2 (Coh2 OS) | Time from initiation of Atezolizumab treatment to death from any cause (until the end of study, approximately 5 years). |
| Percentage of participants with Adverse Events (AEs) | Baseline through the end of study (approximately 5 years) |
| Best overall response (BOR) of overall population | Best response achieved within 12 weeks as assessed in clinical routine, through the end of study (approximately 5 years) |
| Disease control rate (DCR) of overall population | Percentage of patients who achieved a CR, a PR, or stable disease (SD) as evaluated by the physician according to clinical practice at the time of the fifth Atezolizumab infusion; (until the end of study, approximately 5 years) |
Other
| Measure | Time frame |
|---|---|
| Health-related quality of life (HRQoL) | Prior to first Atezolizumab infusion, during Atezolizumab treatment, and post Atezolizumab discontinuation, through the end of study (approximately 5 years) |
Countries
Germany
Outcome results
None listed